[go: up one dir, main page]

MA57399B1 - Inhibition de l'intégrine humaine alpha4beta7 - Google Patents

Inhibition de l'intégrine humaine alpha4beta7

Info

Publication number
MA57399B1
MA57399B1 MA57399A MA57399A MA57399B1 MA 57399 B1 MA57399 B1 MA 57399B1 MA 57399 A MA57399 A MA 57399A MA 57399 A MA57399 A MA 57399A MA 57399 B1 MA57399 B1 MA 57399B1
Authority
MA
Morocco
Prior art keywords
integrin
inhibition
human
diseases
treat
Prior art date
Application number
MA57399A
Other languages
English (en)
Inventor
Bruce N. Rogers
Robert Zahler
Fu-Yang Lin
Cheng Zhong
Eugene Hickey
Tyler DAY
Byungchan Kim
Matthew G. Bursavich
Dan CUI
James E. Dowling
Kristopher N. Hahn
Bryce A. Harrison
Blaise S. LIPPA
Dawn M. Troast
Kyle D. Konze
Aleksey I. Gerasyuto
Salma RAFI
Evelyne HOUANG
Original Assignee
Morphic Therapeutic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic, Inc. filed Critical Morphic Therapeutic, Inc.
Publication of MA57399B1 publication Critical patent/MA57399B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Radio Relay Systems (AREA)
  • Air Conditioning Control Device (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne des petites molécules antagonistes de l'intégrine α4β7 et des procédés d'utilisation de celles-ci pour traiter un certain nombre de maladies et de pathologies.
MA57399A 2019-10-16 2020-10-16 Inhibition de l'intégrine humaine alpha4beta7 MA57399B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916062P 2019-10-16 2019-10-16
EP20875989.4A EP4045039B1 (fr) 2019-10-16 2020-10-16 Inhibition de l'intégrine humaine alpha4beta7
PCT/US2020/055986 WO2021076890A1 (fr) 2019-10-16 2020-10-16 INHIBITION DE L'INTÉGRINE HUMAINE α4β7

Publications (1)

Publication Number Publication Date
MA57399B1 true MA57399B1 (fr) 2025-06-30

Family

ID=73198501

Family Applications (1)

Application Number Title Priority Date Filing Date
MA57399A MA57399B1 (fr) 2019-10-16 2020-10-16 Inhibition de l'intégrine humaine alpha4beta7

Country Status (36)

Country Link
US (3) US20240174632A1 (fr)
EP (3) EP4045039B1 (fr)
JP (7) JP7437490B2 (fr)
KR (2) KR20220102669A (fr)
CN (3) CN115087444B (fr)
AR (1) AR120244A1 (fr)
AU (2) AU2020366435A1 (fr)
BR (1) BR112022007284A2 (fr)
CA (1) CA3154269A1 (fr)
CL (1) CL2022000959A1 (fr)
CO (1) CO2022005759A2 (fr)
CR (1) CR20220205A (fr)
CU (1) CU20220027A7 (fr)
DK (1) DK4045039T3 (fr)
DO (2) DOP2022000081A (fr)
EC (1) ECSP22038978A (fr)
ES (1) ES3035561T3 (fr)
FI (1) FI4045039T3 (fr)
HR (1) HRP20250749T1 (fr)
HU (1) HUE071814T2 (fr)
IL (2) IL319053A (fr)
LT (1) LT4045039T (fr)
MA (1) MA57399B1 (fr)
MD (1) MD4045039T2 (fr)
MX (1) MX2022004406A (fr)
PE (1) PE20221829A1 (fr)
PH (1) PH12022550886A1 (fr)
PL (1) PL4045039T3 (fr)
PT (1) PT4045039T (fr)
RS (1) RS66976B1 (fr)
SI (1) SI4045039T1 (fr)
TW (7) TWI775182B (fr)
UA (1) UA130059C2 (fr)
UY (1) UY38926A (fr)
WO (3) WO2021076890A1 (fr)
ZA (2) ZA202203872B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI856956B (zh) 2018-04-12 2024-10-01 美商莫菲克醫療股份有限公司 人類整合素α４β７拮抗劑
IL282545B2 (en) 2018-10-30 2025-04-01 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
CA3139526A1 (fr) 2019-05-15 2020-11-19 Chemocentryx, Inc. Composes triaryles pour le traitement de maladies pd-l1
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
PH12022550876A1 (en) 2019-10-16 2023-03-27 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
CA3152714A1 (fr) 2019-10-16 2021-04-22 Pingchen Fan Heteroaryl-biphenylamines pour le traitement de maladies pd-l1
KR20220102669A (ko) * 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제
WO2023125182A1 (fr) * 2021-12-27 2023-07-06 海思科医药集团股份有限公司 Dérivé d'acide propionique et son utilisation médicale
WO2024051819A1 (fr) 2022-09-09 2024-03-14 西藏海思科制药有限公司 Dérivé d'acide propionique et son utilisation en médecine
KR20250120367A (ko) 2022-12-22 2025-08-08 신테라, 인크. 알파4 베타7 인테그린 안타고니스트 및 이의 용도
CN120957974A (zh) * 2023-02-21 2025-11-14 希四克斯探索有限公司 大环α4β7整合素抑制剂
CN121335980A (zh) 2023-05-26 2026-01-13 阿达尔克斯制药有限公司 Sod1调节组合物及其使用方法
WO2025026955A1 (fr) * 2023-07-28 2025-02-06 Galapagos Nv Nouveaux composés et compositions pharmaceutiques de ceux-ci pour le traitement de troubles inflammatoires
WO2025176107A1 (fr) * 2024-02-20 2025-08-28 西藏海思科制药有限公司 Dérivés de pyridone et leur utilisation médicale
CN118702712B (zh) * 2024-07-04 2025-11-11 安徽普利药业有限公司 一种n-(3-苯10硼酸)-l-天冬氨酸中间体制备方法
WO2026018016A1 (fr) * 2024-07-19 2026-01-22 C4X Discovery Limited Composés thérapeutiques
WO2026018017A1 (fr) * 2024-07-19 2026-01-22 C4X Discovery Limited Composés thérapeutiques
CN119504796A (zh) * 2024-11-20 2025-02-25 南通大学附属医院 一种具有抗肿瘤活性的化合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2159450C (fr) 1993-03-31 2002-01-08 Norman Anthony Abood 1-amidinophenyl-pyrrolidones piperidinones azetinones, inhibiteurs de l'agregation plaquettaire
DE4427979A1 (de) 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
DE19622489A1 (de) 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
EP0932615A1 (fr) 1996-10-11 1999-08-04 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
WO1998016524A1 (fr) 1996-10-11 1998-04-23 Cor Therapeutics, Inc. DERIVES HETEROCYCLIQUES UTILISES COMME INHIBITEURS DE FACTEUR Xa
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999026921A1 (fr) 1997-11-24 1999-06-03 Merck & Co., Inc. DERIVES D'ALANINE-β AGISSANT EN TANT QU'INHIBITEURS DE L'ADHESION CELLULAIRE
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU4584199A (en) 1998-06-29 2000-01-17 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
EP1100506A4 (fr) * 1998-07-29 2002-06-26 Merck & Co Inc Antagonistes des recepteurs de l'integrine
GB9826174D0 (en) * 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
BR0010349B1 (pt) 1999-05-07 2011-10-04 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
ATE364592T1 (de) 1999-09-24 2007-07-15 Genentech Inc Tyrosinderivate
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
IL154496A0 (en) * 2000-08-30 2003-09-17 Pharmacia Corp GEM-SUBSTITUTED alpha v beta3 INTEGRIN ANTAGONISTS
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10154280A1 (de) 2001-11-05 2003-05-15 Wilex Ag Antagonisten für alpha¶4¶-Integrine
IL163725A0 (en) 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
HUE028441T2 (hu) 2004-09-03 2016-12-28 Genentech Inc Humanizált anti-béta7 antagonisták és alkalmazásaik
WO2006112951A2 (fr) 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Methode de gestion des risques concernant les patients soumis a un traitement a base de natalizumab
WO2006126529A1 (fr) 2005-05-25 2006-11-30 Shionogi & Co., Ltd. Derive de morphinane substitue en position 7 par un carbamoyle et insature en positions 6 et 7
WO2006131200A1 (fr) 2005-06-09 2006-12-14 Ucb Pharma, S.A. Derives de 2,6-quinolinyle, procedes d'elaboration et leur utilisation comme medicaments
CA3127202A1 (en) 2006-02-28 2007-09-07 Biogen Ma Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US20100272680A1 (en) 2009-02-09 2010-10-28 Subramanian Baskaran Piperidinyl Cyclic Amido Antiviral Agents
MX2013011130A (es) 2011-03-31 2013-10-30 Genentech Inc Metodos de administracion de antagonistas de integrina beta7.
AR092908A1 (es) 2012-10-05 2015-05-06 Genentech Inc Metodos para diagnosticar y tratar enfermedad intestinal inflamatoria
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
CN105658641B (zh) 2014-07-25 2018-04-17 江苏恒瑞医药股份有限公司 氮茚‑酰胺类衍生物、其制备方法及其在医药上的应用
EP3224280A1 (fr) * 2014-11-26 2017-10-04 Millennium Pharmaceuticals, Inc. Vedolizumab utilisable en vue du traitement de la maladie de crohn fistulisante
EP3262072A1 (fr) 2015-02-26 2018-01-03 F. Hoffmann-La Roche AG Antagonistes d'intégrine bêta7 et procédés de traitement de la maladie de crohn
EP3589627A4 (fr) * 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
US10246451B2 (en) 2017-04-26 2019-04-02 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
TWI856956B (zh) * 2018-04-12 2024-10-01 美商莫菲克醫療股份有限公司 人類整合素α４β７拮抗劑
CA3115830C (fr) * 2018-10-30 2023-09-12 Gilead Sciences, Inc. Composes pour inhibition de l'integrine .alpha.4.beta.7
IL282545B2 (en) 2018-10-30 2025-04-01 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2020092383A1 (fr) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Composés pour l'inhibition de l'intégrine alpha 4 bêta 7
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
KR20220102669A (ko) 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제

Also Published As

Publication number Publication date
US11370773B1 (en) 2022-06-28
TWI900200B (zh) 2025-10-01
FI4045039T3 (fi) 2025-06-20
US11104661B1 (en) 2021-08-31
BR112022007284A2 (pt) 2022-07-05
JP2024116230A (ja) 2024-08-27
UA130059C2 (uk) 2025-10-29
PE20221829A1 (es) 2022-11-29
PH12022550886A1 (en) 2023-05-03
HRP20250749T1 (hr) 2025-08-15
DK4045039T3 (da) 2025-06-30
WO2021076890A1 (fr) 2021-04-22
CA3154269A1 (fr) 2021-04-22
EP4228634A1 (fr) 2023-08-23
EP4045039A4 (fr) 2023-12-13
CN119192137A (zh) 2024-12-27
EP4559525A3 (fr) 2025-08-20
TWI802477B (zh) 2023-05-11
EP4228634A4 (fr) 2024-12-18
CL2022000959A1 (es) 2023-04-28
TWI888065B (zh) 2025-06-21
RS66976B1 (sr) 2025-07-31
ZA202303992B (en) 2024-06-26
JP7437490B2 (ja) 2024-02-22
JP7437495B2 (ja) 2024-02-22
SI4045039T1 (sl) 2025-07-31
JP7209116B2 (ja) 2023-01-19
TWI840047B (zh) 2024-04-21
JP2024054293A (ja) 2024-04-16
ES3035561T3 (en) 2025-09-04
JP2022548809A (ja) 2022-11-22
WO2021076902A1 (fr) 2021-04-22
JP2023036958A (ja) 2023-03-14
TW202222793A (zh) 2022-06-16
TWI857592B (zh) 2024-10-01
IL319053A (en) 2025-04-01
US20240174632A1 (en) 2024-05-30
AU2020366435A1 (en) 2022-04-21
MD4045039T2 (ro) 2025-11-30
DOP2025000034A (es) 2025-04-08
DOP2022000081A (es) 2022-07-31
CR20220205A (es) 2022-07-22
PT4045039T (pt) 2025-07-02
IL292296B2 (en) 2025-07-01
TWI775182B (zh) 2022-08-21
WO2022081983A1 (fr) 2022-04-21
KR20220102669A (ko) 2022-07-20
EP4045039A1 (fr) 2022-08-24
AU2021361031A1 (en) 2023-06-08
IL292296B1 (en) 2025-03-01
JP2024054296A (ja) 2024-04-16
JP7717202B2 (ja) 2025-08-01
IL292296A (en) 2022-06-01
KR20230088376A (ko) 2023-06-19
AR120244A1 (es) 2022-02-09
TW202126624A (zh) 2021-07-16
JP2022542184A (ja) 2022-09-29
TW202500558A (zh) 2025-01-01
LT4045039T (lt) 2025-08-11
JP7500785B2 (ja) 2024-06-17
TW202500559A (zh) 2025-01-01
JP2023500437A (ja) 2023-01-06
ECSP22038978A (es) 2022-06-30
HUE071814T2 (hu) 2025-09-28
ZA202203872B (en) 2024-01-31
TW202244040A (zh) 2022-11-16
CO2022005759A2 (es) 2022-05-20
JP7702004B2 (ja) 2025-07-02
TW202315868A (zh) 2023-04-16
EP4045039B1 (fr) 2025-04-23
CN116783161A (zh) 2023-09-19
PL4045039T3 (pl) 2025-09-15
TW202332675A (zh) 2023-08-16
EP4559525A2 (fr) 2025-05-28
UY38926A (es) 2021-05-31
TWI791304B (zh) 2023-02-01
CN115087444A (zh) 2022-09-20
MX2022004406A (es) 2022-08-25
WO2021076890A4 (fr) 2021-06-10
CN115087444B (zh) 2024-09-17
CU20220027A7 (es) 2022-12-12

Similar Documents

Publication Publication Date Title
MA57399B1 (fr) Inhibition de l'intégrine humaine alpha4beta7
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
EP4067377A4 (fr) Développement et utilisation d'agents thérapeutiques pour des maladies associées à tslp
MA58373B1 (fr) Inhibiteurs peptidiques du récepteur de l'interleukine-23 et leur utilisation pour traiter des maladies inflammatoires
MA45985A (fr) Inhibiteurs de diacylglycérol acyltransférase 2
MA48772B1 (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA39753B1 (fr) Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
EP3937932A4 (fr) Inhibiteurs de cgaz pour le traitement de maladies auto-inflammatoires et de métastases cancéreuses
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
EP3765611A4 (fr) Oligonucléotides ciblant la pcsk9 pour le traitement de l'hypercholestérolémie et d'états apparentés
EA200700035A1 (ru) Сульфаматные и сульфамидные производные для лечения эпилепсии и родственных di sorders
MA44426B1 (fr) Compositions et méthodes pour diminier l'expression de tau
EP3606520A4 (fr) Inhibiteurs de l'activité de la déshydrogénase à chaîne courte pour le traitement des troubles coronaires
EP3955939A4 (fr) Méthodes et compositions utilisant des vésicules extracellulaires pour la détection de maladies et de troubles
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EP3649256A4 (fr) Procédés de traitement d'une inflammation et de maladies et troubles associés par inhibition de la protéine kinase alpha 1
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3877402A4 (fr) Traitement combiné pour l'hypertension résistante
EP3911153A4 (fr) Traitement de maladies impliquant une déficience d'enpp1 ou d'enpp3
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc
MA53741A (fr) Procédés de traitement de troubles myéloprolifératifs
EP3986554A4 (fr) Ciblage du récepteur de la mélanocortine 3 pour le traitement/la prévention de troubles de l'alimentation, du métabolisme et/ou des troubles émotionnels
EP4073060A4 (fr) Inhibiteurs de l'histone déméthylase spécifique de la lysine pour le traitement de néoplasmes myéloprolifératifs
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires